Familial adenomatous polyposis (FAP) is an autosomal dominant syndrome with almost 100 % risk of colorectal cancer. The typical FAP is characterized by hundreds to thousands of colorectal adenomatous polyps and by extracolonic manifestations, later onset and lower number of polyps in colon is characteristic of an attenuated form (AFAP). We analyzed the APC gene for germline mutations in 90 FAP/AFAP patients. Mutation screening was performed using Denaturing Gradient Gel Electrophoresis. DNA fragments showing an aberrant electrophoretic banding pattern were sequenced. APC-mutation-negative probands were screened for large deletions of the APC gene using multiplex ligation dependent probe amplification. Analysis of mRNA variants followed in probands with possible splicing mutation by PCR amplification of target site flanking exons and sequencing the normal and aberrant products. We identified 30 germline variants among 36 unrelated probands including large deletions. Eleven APC variants detected last two years have not been reported yet. At all, fifteen of them are expected to cause errors in mRNA splicing. Analysis of mRNA in ten of these patients revealed exon skipping in seven cases, exonisation of intron in one of these as well, change of the amount of alternatively spliced product in one case, and no effect was found in three cases. In two of the patients, the biopsy of colon mucosa and polyp enabled us to examine the effect of the mutation on splicing pattern in colon cells directly. The comparison of alternative and standard transcript amount showed similar transcription pattern of exon 14 in control colon mucosa tissue (9 samples) as in 51 blood control samples.

Institute of Biology and Medical Genetics of the 1st Faculty of Medicine and General Teaching Hospital Charles University Prague Albertov 4 Prague 2 128 00 Czech Republic

See more in PubMed

N Engl J Med. 1994 Dec 22;331(25):1694-702 PubMed

Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):3046-50 PubMed

Hum Mutat. 2004 Nov;24(5):370-80 PubMed

Am J Hum Genet. 1998 Jun;62(6):1290-301 PubMed

Ann Oncol. 2011 Apr;22(4):903-909 PubMed

Genomics. 1992 Aug;13(4):1162-8 PubMed

Hum Mutat. 2002 Apr;19(4):460-1 PubMed

Science. 1991 Aug 9;253(5020):661-5 PubMed

Oncogene. 2000 Jan 20;19(3):365-72 PubMed

Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8161-6 PubMed

Cancer Res. 1993 Dec 1;53(23):5589-91 PubMed

Hum Mol Genet. 1993 Mar;2(3):283-7 PubMed

Hum Genet. 1995 Oct;96(4):469-71 PubMed

Cell. 1991 Aug 9;66(3):589-600 PubMed

Proc Natl Acad Sci U S A. 1992 May 15;89(10):4452-6 PubMed

Gut. 1999 Dec;45(6):829-33 PubMed

Hum Mol Genet. 2001 Apr;10(7):721-33 PubMed

Hum Mutat. 1997;9(4):370-3 PubMed

Science. 1996 May 17;272(5264):1020-3 PubMed

Genomics. 1995 Aug 10;28(3):589-91 PubMed

Fam Cancer. 2004;3(1):35-40 PubMed

Nat Med. 1999 Sep;5(9):1071-5 PubMed

Hum Mutat. 1998;Suppl 1:S314-6 PubMed

Hum Mutat. 1992;1(6):467-73 PubMed

Hum Mutat. 2004 Apr;23(4):397 PubMed

Cancer Res. 1994 Jun 1;54(11):2991-5 PubMed

Nat Rev Mol Cell Biol. 2004 Feb;5(2):89-99 PubMed

Cancer. 1995 Dec 15;76(12):2427-33 PubMed

Gene. 2007 Jun 15;395(1-2):8-14 PubMed

Hum Mutat. 1997;10(3):201-6 PubMed

Hum Genet. 1996 Dec;98(6):727-34 PubMed

BMC Med Genet. 2007 Apr 05;8:16 PubMed

Int J Cancer. 2004 Jul 1;110(4):550-7 PubMed

Gut. 2002 Jun;50(6):845-50 PubMed

J Cell Biol. 1996 Jul;134(1):165-79 PubMed

Cancer Res. 1995 Sep 1;55(17):3732-4 PubMed

J Appl Genet. 2008;49(4):407-14 PubMed

Hum Genet. 1995 Dec;96(6):705-10 PubMed

Cell. 1993 Dec 3;75(5):959-68 PubMed

Nat Cell Biol. 2001 Apr;3(4):429-32 PubMed

Am J Hum Genet. 1993 Feb;52(2):273-9 PubMed

Hum Mutat. 1994;3(2):121-5 PubMed

Fam Cancer. 2006;5(2):205-8 PubMed